General Archive
-
News releasesLifeArc funds innovative rare liver disease clinical trial
The first patient has been recruited for the FARGO clinical trial, funded by LifeArc and PSC Support, which explores a…
-
News releasesResearch shows potential ‘life-transforming’ mole reversal therapy in rare condition
Researchers at the Francis Crick Institute, UCL Great Ormond Street Institute for Child Health and Great Ormond Street Hospital for…
-
LifeArc Translational Centres for Rare Diseases
LifeArc Translational Centres for Rare Diseases We have invested £40 million into 4 Translational Centres for Rare Diseases, to unlock…
-
News releasesLifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases
Thousands of people living with rare medical conditions will get access to improved tests, treatments and potentially cures, thanks to…
-
News releasesFirst-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases
Great Ormond Street Hospital (GOSH), supported by LifeArc and Great Ormond Street Hospital Children’s Charity (GOSH Charity), is announcing its…
-
LifeArc-CSO fund for Scottish translational researchers
LifeArc-CSO fund for Scottish translational researchers In association with the Chief Scientist Office (CSO) for the Scottish Government, we support…
-
LifeArc gene therapy innovation fund
LifeArc gene therapy innovation fund The LifeArc Gene Therapy Innovation Fund is a £5m annual fund to support manufacture of…
-
LifeArc and GOSH charity fund
LifeArc and GOSH charity fund LifeArc and GOSH Charity support a joint funding scheme focused on helping GOSH researchers drive…
-
LifeArc and Action medical research fund
LifeArc and Action medical research fund Action Medical Research and LifeArc want to improve the lives of children suffering from…
-
LifeArc Philanthropic fund
The LifeArc Philanthropic Fund The Fund provides grants and funding to academic researchers working to advance new treatments and diagnostics…
-
Repurposing therapies for EB
£2.5 million to develop therapeutics for Epidermolysis Bullosa (EB) LifeArc and DEBRA Austria are partnering to commit £2.5 million to…
-
Translational rare disease centres
Translational rare disease centres With this £40 million we aim to build on the UK’s rich, rare disease research base,…